SNAP Update and ResourcesActualización y recursos de SNAP
On November 1, 2025, the requirements to receive and apply to the Supplemental Nutrition Assistance Program (SNAP) benefits have changed. To see the new policies to request SNAP benefits, click here and/or call 211 for SNAP assistance. Learn more
El 1 de noviembre de 2025, cambiaron los requisitos para recibir y aplicar para los beneficios del Programa de Asistencia Nutricional Suplementaria (SNAP, por sus siglas en inglés). Para consultar las nuevas políticas para aplicar para los beneficios de SNAP, haz clic aquí o llama al 211 para obtener ayuda de SNAP. Aprende Más
Transportation UpdateActualización de transporte
Starting December 15, 2025, SafeRide Health will become the new provider for all member rides to doctor appointments and pharmacy visits. After this date, Texas Children’s Health Plan will no longer use MTM for Non Emergency Medical Transportation (NEMT) services.
For other questions, please call Member Services at the number on the back of your member ID card.
A partir del 15 de diciembre de 2025, SafeRide Health será el nuevo proveedor para todos los viajes de los miembros a citas médicas y visitas a la farmacia. Después de esta fecha, Texas Children’s Health Plan ya no usará MTM para los servicios de Transporte Médico No Urgente (NEMT).
Date: May 20, 2021
Attention: Geneticists, Hematologists, and Oncologists
Effective Date: June 30, 2021Call to action: Effective June 30, 2021, the Texas Health and Human Services Commission (HHSC) will update the enzymes prior authorization criteria to reflect recent FDA-approved administration changes. This impacts the following agents: Adagen (pegademase bovine), Ceprotin (protein C concentrate), Fabrazyme (agalsidase beta), and Revcovi (elapegademase).
Adagen (J2504 procedure code) has been discontinued by the manufacturer.Ceprotin 400-600 units vial is no longer available through retail pharmacy benefits.
The Ceprotin 400-600 units vial will only be available through the medical benefit (procedure code J2724). The 1000 IU single-use vials will continue to be available through the pharmacy benefit.
Clinical prior authorization updates for other enzymes:
Drug
Procedure Code
Changes effective June 30, 2021
Fabrazyme (agalsidase beta)
J0180
Updated age to > 2 years for confirmed Fabry’s disease
Revcovi (elapegademase)
J3590
Updated for diagnosis of adenosine deaminase severe combined immunodeficiency disease (ADA-SCID)
Next steps for providers: Providers should share this communication with their staff. The updated prior authorization forms will be made available near the effective date on the Navitus website (see Resources link below).
Resources:
